Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 4.4% in the afternoon session after the company ...

Curreen Capital breaks down Fortrea’s struggles and turnaround potential. Learn why this CRO stock might rebound and what it means for long-term investors.

Clinical research company Fortrea Holdings (NASDAQ:FTRE) reported Q2 CY2025 results , with sales up 7.2% year on year to $710 ...

Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be reporting results this Wednesday before market open. Here’s ...

Key Points Revenue (GAAP) of $710.3 million for Q2 2025 beat analyst estimates by 12.5%, This result also marked a 7.2% increase over the second quarter of 2024. Adjusted EPS (Non-GAAP) of $0.19 for ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Fortrea ...

The PSUs and RSUs were granted under the Company's 2025 Inducement Award Plan to Mr. Thakral, who was not previously employed by the Company, as an inducement material to Mr. Thakral's employment with ...

We primarily deployed the proceeds from selling Nilorn into Havas in the first quarter and into Fortrea during the second quarter.

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

Veteran clinical research leader Melissa Holbrook has found her next permanent role. | Veteran clinical research leader ...

What Happened? Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 24.1% in the afternoon session after positive earnings reports from industry peers lifted the entire contract ...